Research Article
No access
Published Online: 4 September 2012

Radiation Dosimetry and Biodistribution of the Hypoxia Tracer 18F-EF5 in Oncologic Patients

Publication: Cancer Biotherapy and Radiopharmaceuticals
Volume 27, Issue Number 7

Abstract

The primary goals of this study were to determine the biodistribution and excretion of 18F-EF5 in oncologic patients, to estimate the radiation-absorbed dose and to determine the safety of this drug.
Methods: Sixteen patients with histologically confirmed malignancy received a mean intravenous infusion of 217 MBq (range 107–364 MBq) of 18F-EF5. Over a 4–6-hour period, four to five serial positron emission tomography (PET) or PET/computed tomography (CT) scans were obtained. To calculate the radiation dosimetry estimates, volumes of interest were drawn over the source organs for each PET scan or on the CT for each PET/CT scan. Serial blood samples were obtained to measure 18F-EF5 blood clearance. Bladder-wall dose was calculated based on urine activity measurements.
Results: The urinary bladder received the largest radiation-absorbed dose, 0.12±0.034 mSv/MBq (mean±SD). The average effective dose equivalent and the effective dose of 18F-EF5 were 0.021±0.003 mSv/MBq and 0.018±0.002 mSv/MBq, respectively. 18F-EF5 was well tolerated in all subjects.
Conclusions: 18F-EF5 was demonstrated to be safe for patients, and the radiation exposure is clinically acceptable. As with any radiotracer with primary excretion in the urine, the bladder-wall dose can be minimized by active hydration and frequent voiding.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Wilson WRHay MP. Targeting Hypoxia in cancer therapyNat Rev Cancer201111393. 1. Wilson WR, Hay MP. Targeting Hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393.
2.
Hockel MKnoop CSchlenger K et al. Intratumor pO2 predicts survival in advanced cancer of the uterine cervixRadiother Oncol19932645. 2. Hockel M, Knoop C, Schlenger K, et al. Intratumor pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45.
3.
Nordsmark MOvergaard MOvergaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neckRadiother Oncol19964131. 3. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31.
4.
Brizel DMSibley GSProsnitz LR et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neckInt J Radiat Oncol Biol Phys199738285. 4. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285.
5.
Fyles AMilosevic MHedley D et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancerJ Clin Oncol200220680. 5. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20:680.
6.
Koh W-JRasey JSEvans ML et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazoleInt J Radiat Biol Oncol Phys199222199. 6. Koh W-J, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Biol Oncol Phys 1992;22:199.
7.
Dehdashti FGrigsby PWMintun MA et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response—a preliminary reportInt J Radiat Oncol Biol Phys2003551233. 7. Dehdashti F, Grigsby PW, Mintun MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response—a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233.
8.
Koch CJHahn SMRockwell KJ et al. Pharmacokinetics of the 2-nitroimidazole EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide] in human patients: Implications for hypoxia measurements in vivoCancer Chemother Pharmacol200148177. 8. Koch CJ, Hahn SM, Rockwell KJ, et al. Pharmacokinetics of the 2-nitroimidazole EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide] in human patients: Implications for hypoxia measurements in vivo. Cancer Chemother Pharmacol 2001;48:177.
9.
Koch CJ. Measurement of Absolute Oxygen Levels in Cells and Tissues using Oxygen Sensors and 2-nitroimidazole EF5Methods Enzymol20023523-31. 9. Koch CJ. Measurement of Absolute Oxygen Levels in Cells and Tissues using Oxygen Sensors and 2-nitroimidazole EF5. Methods Enzymol 2002;352:3–31.
10.
Kumar PStypinski DXia H et al. Fluoroazomycin arabinoside (FAZA): Synthesis, 2H and 3H-labelling and preliminary biological evaluation of a novel 2-nitromidazole marker of tissue hypoxiaJ Label Comp Radiopharm1999423. 10. Kumar P, Stypinski D, Xia H, et al. Fluoroazomycin arabinoside (FAZA): Synthesis, 2H and 3H-labelling and preliminary biological evaluation of a novel 2-nitromidazole marker of tissue hypoxia. J Label Comp Radiopharm 1999;42:3.
11.
Evans SMJudy KDDunphy I et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 bindingCancer Res2004641886. 11. Evans SM, Judy KD, Dunphy I, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004;64:1886.
12.
Evans SMJudy KDDunphy I et al. Hypoxia is important in the biology and aggression of human glial brain tumorsClin Cancer Res2004108177. 12. Evans SM, Judy KD, Dunphy I, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177.
13.
Varghese AJWhitmore GF. Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazoleCancer Res1980402165. 13. Varghese AJ, Whitmore GF. Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole. Cancer Res 1980;40:2165.
14.
Raleigh JAKoch CJ. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromoleculesBiochem Pharmacol1990402457. 14. Raleigh JA, Koch CJ. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem Pharmacol 1990;40:2457.
15.
Koch CJScheuermann JSDivgi C et al. Biodistribution and dosimetry of 18F-EF5 in cancer patients with preliminary comparison of 18F-EF5 uptake versus EF5 binding in human glioblastomaEur J Nuc Med Mol Imaging2010372048. 15. Koch CJ, Scheuermann JS, Divgi C, et al. Biodistribution and dosimetry of 18F-EF5 in cancer patients with preliminary comparison of 18F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nuc Med Mol Imaging 2010;37:2048.
16.
Dolbier WRLi A-RKoch CJ et al. [18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedureAppl Radiat Isot20015473. 16. Dolbier WR, Li A-R, Koch CJ et al. [18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 2001;54:73.
17.
Bergman JSolin O. Fluorine-18-labeled fluorine gas for synthesis of tracer moleculesNucl Med Biol199724677. 17. Bergman J, Solin O. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules. Nucl Med Biol 1997;24: 677.
18.
Surti SKarp JS. Imaging characteristics of a 3-dimensional GSO whole-body PET cameraJ Nucl Med2004451040. 18. Surti S, Karp JS. Imaging characteristics of a 3-dimensional GSO whole-body PET camera. J Nucl Med 2004;45:1040.
19.
Stabin MGSparks RBCrowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicineJ Nucl Med2005461023. 19. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023.
20.
Komar GSeppänen MEskola O et al. 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancerJ Nucl Med2008491944. 20. Komar G, Seppänen M, Eskola O, et al. 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008;49:1944.
21.
ICRP Publication 53. Radiation dose to patients from radiopharmaceuticalsAnn ICRP1988181. 21. ICRP Publication 53. Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1988;18:1.
22.
Graham MMPeterson LMLink JM et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studiesJ Nucl Med1997381631. 22. Graham MM, Peterson LM, Link JM, et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med 1997;38:1631.

Information & Authors

Information

Published In

cover image Cancer Biotherapy and Radiopharmaceuticals
Cancer Biotherapy and Radiopharmaceuticals
Volume 27Issue Number 7September 2012
Pages: 412 - 419
PubMed: 22897720

History

Published online: 4 September 2012
Published in print: September 2012
Published ahead of print: 16 August 2012

Permissions

Request permissions for this article.

Topics

    Authors

    Affiliations

    Lilie L. Lin
    *
    Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
    Antti Silvoniemi*
    Department of Otorhinolaryngology-Head and Neck Surgery, Turku University Hospital, Turku, Finland.
    Turku PET Centre, Turku University Hospital, Turku, Finland.
    James B. Stubbs
    Radiation Dosimetry Systems, Alpharetta, Georgia.
    Ramesh Rengan
    Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
    Sami Suilamo
    Turku PET Centre, Turku University Hospital, Turku, Finland.
    Departments of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland.
    Olof Solin
    Turku PET Centre, Turku University Hospital, Turku, Finland.
    Chaitanya Divgi
    Departments of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
    Olli Eskola
    Turku PET Centre, Turku University Hospital, Turku, Finland.
    Jonathan M. Sorger
    Varian Medical Systems, Palo Alto, California.
    Michael G. Stabin
    Department of Radiology and Radiological Sciences, Vanderbilt University, Nashville, Tennessee.
    Alexander Kachur
    Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
    Stephen M. Hahn
    Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
    Tove J. Grönroos
    Turku PET Centre, Turku University Hospital, Turku, Finland.
    Sarita Forsback
    Turku PET Centre, Turku University Hospital, Turku, Finland.
    Sydney M. Evans
    Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
    Cameron J. Koch
    Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
    Heikki Minn
    Turku PET Centre, Turku University Hospital, Turku, Finland.
    Departments of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland.

    Notes

    Address correspondence to: Antti Silvoniemi; Turku PET Centre, Turku University Hospital; Kiinamyllynkatu 4–8; P.O. BOX 52, FI-20521 Turku, Finland
    E-mail: [email protected]

    Disclosure Statement

    Financial support was provided by the Varian Medical Systems.

    Metrics & Citations

    Metrics

    Citations

    Export citation

    Select the format you want to export the citations of this publication.

    View Options

    Get Access

    Access content

    To read the fulltext, please use one of the options below to sign in or purchase access.

    Society Access

    If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

    Restore your content access

    Enter your email address to restore your content access:

    Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

    View options

    PDF/EPUB

    View PDF/ePub

    Full Text

    View Full Text

    Media

    Figures

    Other

    Tables

    Share

    Share

    Copy the content Link

    Share on social media

    Back to Top